Cargando…

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations

The development and spread of drug-resistant phenotypes substantially threaten malaria control efforts. Combination therapies have the potential to minimize the risk of resistance development but require intensive preclinical studies to determine optimal combination and dosing regimens. To support t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wicha, Sebastian G., Walz, Annabelle, Cherkaoui-Rbati, Mohammed H., Bundgaard, Nils, Kuritz, Karsten, Gumpp, Christin, Gobeau, Nathalie, Möhrle, Jörg, Rottmann, Matthias, Demarta-Gatsi, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664866/ https://www.ncbi.nlm.nih.gov/pubmed/36197116 http://dx.doi.org/10.1128/aac.00556-22

Ejemplares similares

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
por: Burgert, Lydia, et al.
Publicado: (2020)

The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro
por: Walz, Annabelle, et al.
Publicado: (2023)

Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance
por: Burgert, Lydia, et al.
Publicado: (2021)

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
por: McCarthy, James S, et al.
Publicado: (2020)

Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection
por: Collins, Katharine A, et al.
Publicado: (2020)

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Using Cryopreserved Plasmodium falciparum Sporozoites in a Humanized Mouse Model to Study Early Malaria Infection Processes and Test Prophylactic Treatments
por: Jiménez-Díaz, María-Belén, et al.
Publicado: (2023)

A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
por: Cherkaoui‐Rbati, Mohammed H., et al.
Publicado: (2022)

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development
por: Andrews, Kayla Ann, et al.
Publicado: (2020)

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2023)

Genetic validation of PfFKBP35 as an antimalarial drug target
por: Thommen, Basil T, et al.
Publicado: (2023)

Immunological memory to blood-stage malaria infection is controlled by the histamine releasing factor (HRF) of the parasite
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2017)

Impact of hemolysis on multi-OMIC pancreatic biomarker discovery to derisk biomarker development in precision medicine studies
por: Searfoss, Richard, et al.
Publicado: (2022)

Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials
por: Sykes, Robert, et al.
Publicado: (2021)

Vector saliva controlled inflammatory response of the host may represent the Achilles heel during pathogen transmission
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2021)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Malaria Parasite-Infected Erythrocytes Secrete PfCK1, the Plasmodium Homologue of the Pleiotropic Protein Kinase Casein Kinase 1
por: Dorin-Semblat, Dominique, et al.
Publicado: (2015)

Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023)

Protection against malaria in mice is induced by blood stage–arresting histamine-releasing factor (HRF)–deficient parasites
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2016)

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
por: McCarthy, James S, et al.
Publicado: (2017)

Hepatic Inflammation Confers Protective Immunity Against Liver Stages of Malaria Parasite
por: Grand, Morgane, et al.
Publicado: (2020)

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
por: Abd‐Rahman, Azrin N., et al.
Publicado: (2020)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
por: Phyo, Aung Pyae, et al.
Publicado: (2016)

Expanding the antimalarial toolkit: Targeting host–parasite interactions
por: Langhorne, Jean, et al.
Publicado: (2016)

Malarial PI4K inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition
por: Demarta‐Gatsi, Claudia, et al.
Publicado: (2022)

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
por: Chughlay, Mohamed Farouk, et al.
Publicado: (2021)

Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle
por: Favuzza, Paola, et al.
Publicado: (2020)

Exposing Anopheles mosquitoes to antimalarials blocks Plasmodium parasite transmission
por: Paton, Douglas G., et al.
Publicado: (2019)

Profiling MHC II immunopeptidome of blood‐stage malaria reveals that cDC1 control the functionality of parasite‐specific CD4 T cells
por: Draheim, Marion, et al.
Publicado: (2017)

Differential Effects of Antimalarial Drugs on Parasite Clearance Rates Are Reflected by Plasmodium falciparum Ring Ratio
por: Saidi, Alexuse M, et al.
Publicado: (2023)

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
por: Llanos-Cuentas, Alejandro, et al.
Publicado: (2018)

Probability of emergence of antimalarial resistance in different stages of the parasite life cycle
por: Pongtavornpinyo, Wirichada, et al.
Publicado: (2009)

Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination
por: Mathews, Emily S., et al.
Publicado: (2018)

Targeting malaria parasite invasion of red blood cells as an antimalarial strategy
por: Burns, Amy L, et al.
Publicado: (2019)

Daily rhythms of both host and parasite affect antimalarial drug efficacy
por: Owolabi, Alíz T Y, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1aajjfjdp9re7read3i1jspio8